PCA(P)(2023)32 - SSP for Utrogestan®
Published: 07/09/23
Purpose
This Circular advises community pharmacy contractors that the UK-wide active Serious Shortage Protocol (SSP) for Utrogestan® (micronised progesterone) 100mg capsules, a hormone replacement therapy (HRT) product, due to expire on 1 September 2023, has now been extended until Friday 29 September 2023.
The extension is applicable to SSP056, which allows community pharmacists to limit the maximum amount given to patients to two months’ supply per prescription.
Background
To To assist in alleviating the current issues with HRT availability, various UK-wide SSPs have been issued by the Department for Health and Social Care (DHSC), in consultation with the Scottish Government. An SSP is an additional tool to manage and mitigate medication shortages for prescribing clinicians, community pharmacies and importantly patients.
Each SSP is individually developed and authorised clinically, to enable community pharmacists and dispensing doctors to dispense a different strength or formulation or alternative medicine or appliances in accordance with the protocol, rather than having to refer prescribing decisions back to the original prescriber. These protocols are time limited.
The DHSC frequently reviews which HRT products should be under an SSP and for how long they need to be in place.
The addition of new SSPs and any amendments or extensions to existing SSPs are documented on the NHS Business Services Authority website using the following link: Serious shortage protocols (SSPs) | NHSBSA.
Enquiries
For any queries on the details of this circular, please contact the Scottish Government Pharmacy Team at PharmacyTeam@gov.scot.
